Author Archives: admin


‘Research Week’ Celebrates UC Merced Innovation | Newsroom – UC Merced University News

By Michelle Morgante, UC Merced

UC Merced celebrates Research Week from March 2-6 to highlight the ground-breaking work taking place on campus.

UC Merced celebrates Research Week from March 2-6 to highlight the ground-breaking work taking place at the University of Californias newest campus.

The annual week of events, sponsored by the Office of Research and Economic Development , is an opportunity for all to see the innovative projects emerging from UC Merced.

Research Week is a fantastic opportunity to have an up-close experience with the newest research from across disciplines emerging from our campus work that will shape our future, said Vice Chancellor for Research and Economic Development Sam Traina. We encourage everyone to come out and learn about the great things happening at UC Merced.

The community is invited to participate in events, talks and tours throughout the week. Several events are specifically organized to engage the public:

Addressing Climate Change, presented by the Sierra Nevada Research Institute

Monday, March 2, 10 a.m.-12:15 p.m. in the California Room

Researchers will hold a series of presentations on efforts to address climate change. At 11:45 a.m., the 25-minute film Beyond the Brink - Californias Watershed will be presented. The program includes lunch and a poster session.

Tours of the Merced Vernal Pools and Grassland Reserve are offered as part of Research Week.

Core Facilities Tours

Tuesday, March 3, 1-3 p.m. starting from the Science and Engineering Building 1 Breezeway

The public is invited to participate in tours of the campuss core facilities: the Merced Vernal Pools and Grassland Reserve; the Stable Isotope Laboratory; the Stem Cell Instrumentation Foundry; the Department of Animal Research Services; the Environmental Analytical Laboratory; the Imaging and Microscopy Facility; the Nuclear Magnetic Resonance Lab; the MERCED (Multi-Environmental Research Computer for Exploration and Discovery) Cluster, and the WAVE (Wide Area Visualization Environment) Lab.

Tours of all facilities except the reserve begin at 1 p.m. and depart every 30 minutes. Tours of the Merced Vernal Pools and Grassland Reserve depart promptly at 1 p.m. and 2:30 p.m. and last 90 minutes. Participation is on a first-come, first-served basis.

It is exciting to be able to open up these important facilities to the local community, Traina said. These spaces, and the instruments and resources they contain, are part of the reason why UC Merced is a top-tier research institution.

Poster Showcase/Merced County Office of Education STEM Fair

Wednesday, March 4, 9:30 a.m.-1 p.m. in the Joseph Edward Gallo Recreation and Wellness Center Gym

The annual exhibit of posters by UC Merced undergraduate and graduate students in all disciplines will be displayed and serve as inspiration to Merced County 5th- through 8th-grade students who have advanced from STEM fairs at the school district level. The STEM Fair is the qualifying event for the California Science and Engineering Fair, and the younger students will present their projects, go on a tour of UC Merced, have lunch with UC Merced researchers and administrators and participate in hands-on science displays by campus scientists. The campus community is encouraged to come see UC Merced students research posters and meet some of Merced Countys brightest young scientists in the STEM Fair.

The Merced County Office of Education STEM Fair is held in conjunction with Research Week.

GradSTORY, presented by RadioBio

Thursday March 5, 10 a.m.-2 p.m.; The Pavilion dining commons

Graduate students will discuss their research and their journeys to graduate school through brief interviews with the proudcers of the RadioBio podcast.

ReCCES Community Reception

Thursday, March 5, 5 p.m.-6:30 p.m., Merced Civic Center-Sam Pipes Room

The Resource Center for Community Engaged Scholarship and the Undergraduate Research Opportunities Center welcome the community to a reception where people can hear from professors conducting community-engaged research and meet undergraduate and graduate students to learn about their involvement in the community. Refreshments provided.

CITRIS Ag-Food Tech Spring Seminar

Friday, March 6, Noon., Classroom and Office Building 2, room 140

Melba Crawford, associate dean of Engineering for Research at Purdue University, is the featured speaker of the Ag-Food Tech Spring Seminar by the Center for Information Technology Research in the Interest of Society.

More information about Research Week events can be found online.

See the rest here:
'Research Week' Celebrates UC Merced Innovation | Newsroom - UC Merced University News

The global single-cell analysis market is projected to reach USD 5.6 billion by 2025 from USD 2.1 billion in 2019, at a CAGR of 17.8% – GlobeNewswire

New York, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Single-cell Analysis Market by Cell Type, Product, Technique, Application, End User - Global Forecasts to 2025" - https://www.reportlinker.com/p04579530/?utm_source=GNW However, the high cost of single-cell analysis products is expected to restrain the growth of this market to a certain extent during the forecast period.

The academic & research laboratories segment accounted for the largest market share in 2018On the basis of end user, the single-cell analysis market is segmented into academic and research laboratories, biotechnology and pharmaceutical companies, hospitals and diagnostic laboratories, and cell banks and IVF centers.The academic and research laboratories segment accounted for the largest market share in 2018.

Factors such as growth in funding for life science research and the increasing number of medical colleges and universities are driving the growth of this end-user segment.

Flow cytometry is the largest technique segment of the single-cell analysis marketBased on technique, the single-cell analysis market is segmented into flow cytometry, NGS, PCR, microscopy, mass spectrometry, and other techniques.The flow cytometry segment accounted for the largest market share in 2018.

The large share of this segment is attributed to the wide usage of flow cytometry in detecting and measuring the physical and chemical characteristics of a population of cells or particles.

North America will continue to dominate the single-cell analysis market in 2025The single-cell analysis market, by region, is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.In 2018, North America accounted for the largest share of the single-cell analysis market.

The large share of North America can be attributed to the increasing drug development activities in the pharmaceutical and biotechnology industries, rising prevalence of chronic and infectious diseases, and an increase in stem cell research activities.

The breakup of primary participants is as mentioned below: By Company Type - Tier 1: 45%, Tier 2: 30%, and Tier 3: 25% By Designation - C-level: 35%, Director-level: 25%, and Others: 40% By Region - North America: 40%, Europe: 20%, Asia Pacific: 25%, Latin America: 10%, and the Middle East & Africa: 5%

Prominent players in the single-cell analysis market include Becton, Dickinson and Company (US), Danaher Corporation (US), Merck Millipore (US), QIAGEN (Netherlands), Thermo Fisher Scientific (US), General Electric Company (US), 10x Genomics (US), Promega Corporation (US), Illumina (US), Bio-Rad Laboratories (US), Fluidigm Corporation (US), Agilent Technologies (US), NanoString Technologies (US), Tecan Group (Switzerland), Sartorius AG (Germany), Luminex Corporation (US), Takara Bio (Japan), Fluxion Biosciences (US), Menarini Silicon Biosystems (Italy), and LumaCyte (US).

Research Coverage:The report analyzes the single-cell analysis market and aims at estimating the market size and future growth potential of this market based on various segments such as product, cell type, technique, application, end user, and region. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the ReportThe report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights into: Market Penetration: Comprehensive information on the product portfolios of the top players in the single-cell analysis market. The report analyzes this market by product, application, cell type, technique, end user, and region Market Development: Comprehensive information on the lucrative emerging markets by product, application, cell type, technique, end user, and region Market Diversification: Exhaustive information about products, growing geographies, recent developments, and investments in the single-cell analysis market Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of leading players in the single-cell analysis marketRead the full report: https://www.reportlinker.com/p04579530/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Here is the original post:
The global single-cell analysis market is projected to reach USD 5.6 billion by 2025 from USD 2.1 billion in 2019, at a CAGR of 17.8% - GlobeNewswire

Hawaii Five-0 To End After 10 Seasons On CBS, Sets Two-Hour Series Finale – Deadline

EXCLUSIVE: CBS Hawaii Five-0 will be coming to an end. The popular action crime drama series will wrap its 10-year, 240-episode run with a two-hour series finale on Friday, April 3.

Primetime-Panic

Your Complete Guide to Pilots and Straight-to-Series orders

Developed by Peter M. Lenkov, Alex Kurtzman and Roberto Orci as a reimagining of Leonard Freemans classic series and shawrun by Lenkov for the shows entire run, Hawaii Five-0 has been a strong profit generator for CBS. In addition to its solid ratings performance, initially on Monday, and as a Friday anchor for the past seven seasons, Hawaii Five-0 has been a big international seller for CBS TV Studios, seen in more than 200 countries. Additionally, it was the last broadcast drama series to score a blockbuster off-network deal, landing $2 million an episode from TNT during its first season on CBS.

Its never easy to say goodbye to a hit franchise that carried on the legacy of the original with such distinction while establishing its own signature style, said Kelly Kahl, President, CBS Entertainment. From episode one, Hawaii Five-0 has been a huge success for us. Thanks to the amazing talents of the producers, writers, cast and crew, it has played a key role for a decade on our schedule and helped establish our powerhouse Friday night. We cannot be prouder of its quality, longevity and are thankful for the passionate fan-devotion it inspired.

Hawaii Five-0 will end its run with its original stars Alex OLoughlin as McGarrett and Scott Caan as Danno. I hear both of their current contracts are up at the end of this season. OLoughlin suffered a serious back injury during the early seasons of the show, and has been dealing with effects from it ever since. There was speculation that he may leave the show two years ago but he stayed on after receiving stem cell treatment. I hear this time around, he felt he could not continue. I hear the network explored continuing Hawaii Five-0 with Caans Danno and a new partner but, ultimately, everyone decided this was the right time to end the series.

This show has been pretty much every waking moment for the last 10 years of my life, said OLoughlin. Everywhere I go on this planet, in every language, I am McGarrett to all these people. What weve done, what weve accomplished, its extraordinary. I cant really put words to express my level of gratitude. Im just glad to have been a part of this, a part of history and Im going to miss it. And to the fans, I dont know how to thank you guys. Thank you for following us the way you have. Im going to miss you. Aloha.

Launching a Hawaii Five-0 reboot had been a top priority for CBS TV Studios for more than a decade. There were multiple unsuccessful attempts with other writers and producers until Lenkov came on board, teaming with Kurtzman and Orci for the pilot. It was the first of a slew of successful reboots Lenkov has delivered for CBS and CBS TV Studios.

Hawaii Five-0 has been such a blessing to me and all of the people who have worked on this incredible show, said Lenkov. I truly learned the meaning of ohana as the viewers embraced us and the people of Hawaii welcomed us with the privilege to film on their shores. I am forever indebted to the creative genius that was Leonard Freeman who gave us such a beautiful story to begin with. And my eternal gratitude to our cast, led by our hero Alex OLoughlin, the writers, the production team, our CBS ohana, and most importantly YOU, the fans, who allowed us to come to work with pride and made our series such a success. Mahalo.

Hawaii Five-0 currently stars OLoughlin, Caan, Ian Anthony Dale, Meaghan Rath, Beulah Koale, Katrina Law, Taylor Wily, Dennis Chun, Kimee Balmilero and Chi McBride.

Like most long-running series, it went through multiple cast transitions. That included the controversial exit of original co-stars Daniel Dae Kim and Grace Park after Season 7. Returning for the two-hour finale are recurring cast members James Marsters (Victor Hesse), William Sadler (John McGarrett) and Mark Dacascos (Wo Fat).

Hawaii Five-0, which consistently wins its time period, has been watched by almost 40 million viewers this season. In addition, the show has ranked in the top 15 or higher of broadcast dramas during its run. Also, Hawaii Five-0, is CBS most social primetime drama, generating 47 million impressions, 3.7 million engagements and 3.8 million video views, season-to-date.

For 10 seasons, Alex, Scott and the rest of the talented Five-0cast have brought fans exciting adventures in a spectacular tropical paradise, said David Stapf, President, CBS Television Studios. We specifically want to thank Peter and the incredibly talented production team for 10 years of consistently outstanding television. The drama has been a great success for the Studio and Network, and as a global franchise for our company. Were pleased to give it a big sendoff and that viewers will have the opportunity to say goodbye to their favorite characters as the final season wraps.

Lenkov executive produces the series with David Wolkove, Matt Wheeler, Kurtzman and Orci.

Link:
Hawaii Five-0 To End After 10 Seasons On CBS, Sets Two-Hour Series Finale - Deadline

Everything you need to know about Myeloma – IOL

By Partnered Content 3h ago

Share this article:

Most of you reading this would have probably never heard of such a disease. My hope is, after taking time to read this, that you will know what myeloma is and have a better understanding of bone marrow cancer in general.

So, lets get started!

Your bone marrow is the factory where all your blood cells are made. This includes red blood cells (they carry the oxygen in your blood), white blood cells (your bodys defence against infections) and platelets (small fragments that prevent and stop bleeding).

The production of these cells by the bone marrow is very well controlled by your body, both in terms of the amount and the type of cells produced. If you have an infection, for instance, your body tells the stem cells in your bone marrow to make more white blood cells to help fight the infection. In such instances, an immature, baby cell gets produced in your bone marrow which then needs to go through various stages of growth and development to become a mature white blood cell. It is then released from the bone marrow into your bloodstream to go and do the job it was destined for, to fight the infection.

This process usually runs quite smoothly, but things can, unfortunately go horribly wrong. Sometimes your body makes a mistake in the production of a white blood cell, almost like a programming error which occurs in the DNA (blueprint) of the cell. It often recognizes its mistake and corrects it, but occasionally this abnormal cell has the ability to hide from your bodys defences, doesnt listen to your bodys commands anymore and can start to increase in number without anything controlling it. This causes a variety of problems and is then called cancer.

Depending on the type of white blood cell and where in its development the programming error occurs, a person can either develop a type of bone marrow cancer (usually leukaemia or myeloma) or lymphoma (glandular cancer), which is also a type of cancer that develops from an abnormal white blood cell.

That brings us to myeloma (also called multiple myeloma or plasma cell myeloma). Myeloma is a type of bone marrow cancer that develops when a programming error occurs in the development of a specific type of white blood cell, called a plasma cell. To understand myeloma better, it is important to understand what role a plasma cell plays under normal circumstances.

They are indeed an integral part of your bodys immune system. Any infection that you may develop gets recognized by your plasma cells. They respond by rapidly producing small proteins called antibodies, which are almost like homing missiles, programmed to go and destroy only that specific virus or bacteria that is making you ill.

After an infection, some of the antibodies remain in your bloodstream and if you are exposed to that exact virus or bacteria again, they are ready to attack immediately, thereby limiting the infection. This is the rationale behind childhood vaccination; to stimulate the production of antibodies which patrol your bloodstream and protect you when you get exposed to infections like measles, polio and many others.

If these plasma cells become cancerous however, they rapidly increase in number, taking over the bone marrow and producing a massive amount of an abnormal antibody which can cause a whole array of problems. This increase in antibody levels in the bloodstream can be measured with a blood test and is also used to monitor the response to treatment.. What are thesymptoms of myeloma?

The abnormal plasma cells in the bone marrow overwhelms the normal bone marrow which most commonly leads to an inability to produce enough red blood cells. This is called anaemia. Symptoms of anaemia are related to the bodys inability to carry sufficient oxygen to your organs and include worsening fatigue, shortness of breath and dizziness.

The abnormal plasma cells also have the ability to weaken your bones. This can either be a generalized loss of bone strength (called osteoporosis), or it can lead to numerous holes being eaten in your bones. This can be seen on an X-Ray or other types of scans. It often results in significant bone pain or even worse, severe fractures with minimal- or even no trauma at all.

Bones are rich in calcium, and if they are being eaten away, their calcium content is released into the bloodstream causing an elevated blood calcium level. This can lead to dehydration, kidney failure and numerous other symptoms.

As mentioned before, the plasma cells in the bone marrow releases a massive amount of abnormal antibodies into the bloodstream. They can clog up your kidneys and cause significant- and often irreversible kidney failure. This can seriously complicate the management of the disease.

These are by far the most common features of myeloma:

Anaemia, bone lesions or fractures, hypercalcaemia and kidney failure.There are numerous other symptoms which can occur, albeit less common.

Is myeloma treatable?

Myeloma is indeed a treatable condition, but there are a couple of important treatment principles to understand.

For most people, myeloma is not a curable disease. It can, however, be carefully managed and the aim of treatment is to provide a good quality of life for as many years as possible. No patients disease is the same and where we sometimes have patients with myeloma living in excess of ten years after being diagnosed, other patients are unfortunately less fortunate and have a form of the disease that is resistant to treatment which can take its toll after only a couple of months.

We perform DNA-tests on the cancer cells and look at various other blood results in an attempt to identify those patients with high-risk disease, who potentially need more intense treatment than others.

The goal of treatment is to destroy as many abnormal plasma cells in the bone marrow as possible. This leads to recovery of the normal bone marrow and minimises the risk of any further complications, giving the body a chance to recover from any complications caused prior to treatment.

For many decades, the backbone of the treatment for myeloma was a combination of two different type of drugs: Chemotherapy and high dosages of cortisone. This is usually quite well tolerated.

The last couple of years, however, have seen an explosion of newer therapies for the treatment of myeloma. This started years ago with the discovery that Thalidomide, was extremely effective for the treatment of myeloma. Soon, more of these so-called novel therapies were developed, leading to a significant increase in the survival of patients who have access to these drugs.

The latest and most impressive of these treatments are certainly the development of monoclonal antibodies and CAR-T cells, both of which are extremely effective even in high risk or resistant myeloma. There is so much excitement about all the newer therapies, but access remains a challenge in theSouth African market.

A strong collaborative effort is required amongst pharmaceutical companies, government and medical schemes, to improve the current access of newer drugs. Nevertheless, some of these drugs have been around for many years and the costs have come down considerably, making it accessible to more people.

The initial treatment of myeloma generally consists of varying combinations of these drugs depending on the patients age, physical condition and of course, the available funding.

We usually use 3 different drugs in combination (a so-called triplet regimen) which has been proven to be very effective. Once the treatment is started, we take blood regularly to monitor the abnormal antibody levels in the blood which, as mentioned earlier, is a surrogate indicator of the number of cancer cells remaining in the bone marrow.

If we dont see a significant downward trend, the disease is likely resistant to that specific treatment combination and treatment should be adjusted accordingly. However, if the antibody levels come down significantly, we are on the right track and can continue with the same treatment until an optimal response is obtained or the development of side-effects forces us to make an adjustment.

After 4-6 months of treatment, the hope is to see no sign of any abnormal antibodies or cancer cells anymore (we call this a remission), or at least a dramatic reduction. We do however know that although we sometimes dont pick up any sign of residual disease, it is merely because the available tests are not sensitive enough. There will always be some cancer cells that remain.

As a general principle, however, the less residual disease, the longer it usually takes before it causes problems again. Because of this, we usually treat younger patients more aggressively in an attempt to obtain a deeper remission. The biggest difference in younger patients is the use of an autologous stem cell transplant as a 2nd phase of treatment to try and obtain or deepen a remission.

We harvest the patients bone marrow stem cells and keep them frozen until needed. We then administer a single high dose chemotherapy which destroys many of the remaining cancer cells, but in the process, it also destroys the normal bone marrow, without which you cannot survive. The patients stem cells are then thawed and given back to them like a blood transfusion.

After about two weeks of close monitoring in the hospital, the stem cells start to function and the patient subsequently has his/her own bone marrow back, hopefully with significantly less myeloma. The age cut-off for such a procedure is arbitrary because it largely depends on the physical condition of the patient. Most people in South Africa, however, use the age of 70 as a cut off, sometimes a bit older if the patient is in exceptional condition for his/her age.

The median age of people diagnosed with myeloma worldwide is about 70 years. The available data, however, suggests that the median age in South Africa is considerably younger, somewhere around the age of 60 years. Due to this, as well as the problems with drug availability in South Africa, we often rely quite heavily on stem cell transplantation as an important part of treatment. If enough stem cells are harvested and cryopreserved, such a transplant can be repeated on numerous occasions to improve disease control.

After a transplant, as well as for those patients who are not candidates for a transplant, a form of low-intensity maintenance therapy is often started as the next phase of treatment in an attempt to keep the disease under control for as long as possible. This duration varies considerably. We hope for a couple of years, but it is unfortunately sometimes just a couple of months before the disease worsens, after which more intense treatment needs to be restarted again and the above cycle repeats itself. The remission duration gives us a good indication regarding the nature and prognosis of the disease.

There is so much more detail about myeloma to share, but the bottom line is this: Although myeloma is not a curable cancer and can lead to devastating complications, there is good treatment available which can help many patients enjoy a good quality of life for many years.

It is important to diagnose myeloma early, so if you have some of the symptoms mentioned earlier, please contact your General Practitioner for further investigation. If any abnormalities are detected, your GP can refer you to aClinical Haematologist, who specialises in bone marrow cancers and are best equipped to treat your myeloma.

We are all very excited about the future of myeloma treatment and hope that the treating physicians, pharmaceutical companies and government can take hands to ensure proper treatment for all the people in South Africa who suffer from this disease.

This article was compiled by Dr. Hannes Koornhof (Chairman of SACHAS)MBChB, FCP (SA), Dip HIV Man (SA), Cert Clin Haematology (SA) PhysSponsored by JANSSEN PHARMACEUTICA(PTY) LTD/(EDMS) BPK. (Reg. No./Regnr. 1980/011122/07); No 2, Medical Road, Halfway House, Midrand, 1685.www.janssen.com.

Medical Info Line: 0860 11 11 17. EM-27036

See original here:
Everything you need to know about Myeloma - IOL

2020-2025 Global and Regional Stem Cell Alopecia Treatment Industry Production, Sales and Consumption Status and Prospects Professional Market…

The global Stem Cell Alopecia Treatment market report by HNY Research offers users a detailed overview of the market and all the main factors affecting the market. The study on global Stem Cell Alopecia Treatment market, offers profound understandings about the Stem Cell Alopecia Treatment market covering all the essential aspects like revenue growth, supply chain, sales, key players and regions. There is a target set in market that every marketing strategy has to reach. This report on Stem Cell Alopecia Treatment focusses on different categories that define this market with a systematic approach that addresses the consumer base, researchers and market experts like the stakeholders. It also gives a clear perspective towards the competition and demand and supply chain.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4359779

Manufacturer Detail

By Market Players:

By Application

By TypeAlopecia Areata, Alopecia Totalis, Alopecia Universalis

The Stem Cell Alopecia Treatment market report also offers some presentations and illustrations about the market that comprises pie charts, graphs, and charts which presents the percentage of the various strategies implemented by the service providers in the global Stem Cell Alopecia Treatment market. This report on Stem Cell Alopecia Treatment has been very well drafted to benefit anyone studying it. There are different marketing strategies that every marketer looks up to in order to ace the competition in the Global market. Some of the primary marketing strategies that is needed for every business to be successful are Passion, Focus, Watching the Data, Communicating the value To Your Customers, Your Understanding of Your Target Market. Every market research report follows a robust methodology to define its market value. By doing so, the Stem Cell Alopecia Treatment research study by HNY Research offers collection of information and analysis for each facet of the Stem Cell Alopecia Treatment market such as technology, regional markets, applications, and types.

Browse the complete report @ https://www.orbisresearch.com/reports/index/2020-2025-global-and-regional-uterine-fibroids-treatment-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report

This study can benefit investors and business owners in many ways. It studies the business models, strategies, growth, innovations and every information about manufacturers that can help make business predictions and fetch good results. Making right business decisions is an undeniable measure that needs to be taken for market growth. Every market has a set of manufacturers, vendors and consumers that define that market and their every move and achievements becomes a subject of studying for market researchers and other stakeholders. One of the most important aspects focused in this study is the regional analysis. Region segmentation of markets helps in detailed analysis of the market in terms of business opportunities, revenue generation potential and future predictions of the market. For Stem Cell Alopecia Treatment report, the important regions highlighted are North America, South America, Asia, Europe and Middle East. Another important aspect of every market research report by HNY Research is the study of the key players or manufacturers driving the market forward. The process helps to analyze the opponent thoroughly.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4359779

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155Email ID: [emailprotected]

Read more from the original source:
2020-2025 Global and Regional Stem Cell Alopecia Treatment Industry Production, Sales and Consumption Status and Prospects Professional Market...

Researchers found a cure for diabetes (in lab mice) – The Next Web

More than 34 million Americans have diabetes, approximately 10% of the population according to the American Diabetes Association. To date, the most common treatment has been to manage the disease with a carefully controlled diet and regular insulin shots, if needed. But a cure may be on the horizon.

A research team led by Jeffrey Millman at Washington University in St. Louis, Missouri found last year that infusing mice with stem cells could offer a better treatment option.

Building on that research, the same team may have found a cure: at least in lab mice.

Diabetics are characterized by their difficulty producing or managing insulin. This requires careful monitoring, a strict diet, exercise, and expensive insulin shots which many diabetics find themselves rationing due to the cost of drugs in the United States. Insulin is normally produced in the pancreas, but those with diabetes dont produce enough of it. To treat diabetes, many diabetics have to monitor their blood sugar levels, and inject insulin directly into the bloodstream as needed. Millmans treatment foregoes these shots and instead uses beta cells to secrete the insulin for you.

The treatment relies on induced pluripotent stem cells (iPS cells). These cells are essentially a blank slate and can be tricked into becoming almost any other type of cell in the body.

In a new study, the team improved on the technique it had developed last year to produce and introduce these cells into the bloodstream. When converting the stem cells into another type of cell, there are always mistakes and random cells enter into the mix along with the insulin-producing ones. These cells are harmless, but they dont pull their weight.

The more off-target cells you get, the less therapeutically relevant cells you have, Millman told New Atlas. You need about a billion beta cells to cure a person of diabetes. But if a quarter of the cells you make are actually liver cells or other pancreas cells, instead of needing a billion cells, youll need 1.25 billion. It makes curing the disease 25% more difficult.

The new method would rid the sample of those unwanted cells. Millmans team built a process that targeted the cytoskeleton, the structure that gives the cells their shape, and produced not only a higher percentage of effective beta cells, but better functioning ones.

When these new cells were infused into diabetic mice, their blood sugar levels stabilized, leaving them functionally cured of the disease for up to nine months.

Granted, its just an animal trial. The results shouldnt be interpreted as a cure for humans. But its a promising start.

The team plans to continue testing the cells in larger animals, and over longer periods, with their sights set on human clinical trials in the future.

Read next: Smithsonian Institute just released 2.8 million high-quality images for free

See the original post:
Researchers found a cure for diabetes (in lab mice) - The Next Web

United Therapeutics: Buy The Dip – Seeking Alpha

On February 26, United Therapeutics (UTHR) came out with earnings results for the fourth quarter of 2019. The companys revenues of $311.11 million were down YoY by 18.43% and fell short of the consensus by $46.06 million. The companys fourth-quarter non-GAAP EPS (earnings per share) of $1.96 also missed the consensus by $1.43.

Subsequently, the stock is down by 11.97% from $112.86 on February 25 to $100.79 on February 27. I believe that this is an investor overreaction, considering that the dip in revenues and EPS is associated with a one-time event of inventory destocking by a distributor in the fourth quarter. Earlier in 2019, this distributor had placed larger-than-normal orders for the companys products due to an error in its patient utilization data. Hence, the smaller-than-normal order in the fourth quarter was an attempt to normalize inventory levels.

Besides this small glitch, the company boasts of robust fundamentals. Today, we will see why United Therapeutics can prove to be an attractive opportunity in 2020.

United Therapeutics is a biotechnology company focused on developing novel, life-extending therapies in lung disease, oncology, and organ manufacturing indications. The company commercializes therapies including an infused formulation of the prostacyclin analog treprostinil, Remodulin; an inhaled formulation of treprostinil, Tyvaso, and a tablet dosage form of treprostinil, Orenitram; and an oral PDE-5 inhibitor, Adcirca, in PAH (pulmonary arterial hypertension) indication. The company also offers Unituxin, a monoclonal antibody for treating neuroblastoma.

United Therapeutics is now working on developing next-generation technologies for Remodulin, Tyvaso, and Orenitram. The companys R&D pipeline also has investigational novel biologics and NCEs (new chemical entities) targeting various lung, oncology, and organ manufacturing indications.

In July 2002, the company secured FDA approval for Remodulin as a continuous subcutaneous infusion for the treatment of PAH patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise. Despite the launch of a generic treprostinil in early 2019, Remodulins sales were only 2% down YoY to $587 million in 2019. In fact, the company reported the highest number of new Remodulin starts in the last ten years.

The YoY decline in Remodulin sales was attributed to a small number of patients switching to the generic drug, as well as to the fact that new patients start on lower dosages of Remodulin and then begin the process of titrating to their effective dose. Since the patient switching trend has all but trickled down, the company now expects U.S. Remodulin patient demand as well as sales to jump up YoY in 2020.

Remodulin demand has been pretty sticky for years. It is a very complex product targeting a very fragile patient population, which places a high premium on years of safety and supply chain reliability.

United Therapeutics is now getting ready to launch the subcutaneous delivery system for Remodulin injections, the RemUnity system, in July 2020. Co-developed by United Therapeutics and Deka Research and Development and cleared by FDA under the FDA 510(K) pathway, the RemUnity system is expected to reduce the risk of bolus dosing due to pump failures and provides wider arrays of notifications, alerts, and alarms than current pumps. Additionally, the RemUnity system will control Remodulin flow rates without the use of a motor. The pump is small and lightweight with a service life of at least three years.

On February 24, the company announced preliminary analysis from Phase 3 INCREASE study evaluating Tyvaso Inhalation Solution in patients suffering from WHO (World Health Organization) Group 3 pulmonary hypertension associated with PH-ILD (interstitial lung disease). The trial met its primary endpoint of demonstrating improvement in 6MWD (six-minute walk distance). In addition to increasing six-minute walk distance by 21 meters versus placebo after 16 weeks of treatment, Tyvaso also demonstrated significant improvements in each of the study's secondary endpoints, including reduction in the cardiac biomarker NT-proBNP, time to first clinical worsening event, change in peak 6MWD at Week 12, and change in trough 6MWD at week 15. Based on the INCREASE results, the company now plans to submit a supplemental new drug application to expand the Tyvasos label in mid-2020.

In June 2019, the company submitted a 505(B)(1) NDA (new drug application) for Trevyent disposable treprostinil pump system. Although the FDA first accepted the application and set PDUFA (prescription drug user fee act) date as April 27, 2020, the agency later included a mid-cycle information request noting several deficiencies in the Trevyent NDA. While the company has already sent its responses to the FDA, based on recent discussions with the FDA, the company expects a delay in the PDUFA date. The company expects this FDA approval in the next 18 months.

United Therapeutics also expects the launch of ISR (Implantable System for Remodulin) codeveloped with Medtronic (MDT) to be delayed to 2021. The delay of the commercial launch is attributable to Medtronic satisfying various conditions to its PMA approval.

United Therapeutics estimates the prevalence of PAH WHO Group 1 in the U.S. to be more than 45,000. The currently approved PAH drugs are for PAH WHO 1 class patients. According to PHA (Pulmonary Hypertension Association), WHO Group 1 refers to pulmonary arterial hypertension (PAH), which is caused when the arteries in the lungs become narrowed, thickened or stiff. The right side of the heart must work harder to push blood through these narrowed arteries. This extra stress can cause the heart to lose its ability to pump enough blood through the lungs to meet the needs of the rest of the body.

However, the prevalence of PAH WHO Group 3 patients in the U.S is even higher, of around more than 130,000 patients. These patients do not have any FDA approved treatment option. Again, according to PHA, WHO Group 3 includes PH due to chronic lung disease and/or hypoxia (low oxygen levels). These lung diseases include obstructive lung disease where the lung airways narrow and make it harder to exhale (e.g. COPD or emphysema); restrictive lung disease in which the lungs have a tough time expanding when one inhales (e.g. interstitial lung disease or pulmonary fibrosis); sleep apnea, and living in an area of high altitude for a long period of time. Arteries in the lungs tighten so that blood can only go to areas of the lungs that are receiving the most air and oxygen. This tightening leads to high blood pressure throughout the lungs.

United Therapeutics is working to increase its total patient base from around 7,500 to 25,000 in the next five years.

Besides Remodulin, Tyvaso and Orenitram also saw the highest patient demand in 2019 as compared to the last four years.

Then again, United Therapeutics expects RemUnity, Trevyent, ISR, and Smart Pump technology to have a very favorable impact on future patient demand and sales of Remodulin. The company also expects label expansion of Tyvaso based on the INCREASE study to increase the addressable U.S. population by more than 30,000 patients. This will also position the Tyvaso as a treatment option for a section of the PAH WHO Group 3 patients, those with interstitial lung disease. The company is studying Tyvaso in COPD (chronic obstructive pulmonary disorder) patients in the Phase 3 PERFECT study. Finally, the expanded label of Orenitram based on the FREEDOM-EV trial highlighting superior morbidity and mortality outcomes is also helping to attract new PAH patients.

United Therapeutics is now studying Tyvaso in PH WHO Group 3 patients, PH COPD patients, in Phase 3 trial PERFECT. The company seems to have high hopes for the success of the trial after robust results from the INCREASE study since inhaled therapies can avoid the VQ (Ventilation Perfusion Mismatch), as is seen in system therapies targeting lung diseases. The PERFECT trial is currently 20% enrolled.

Besides studying already approved products for additional indications, the company also has a slew of investigational NCEs and biologics in its pipeline.

United Therapeutics expects investigational Phase 3 asset, ralinepag, to transform the care of WHO Group I PH patients. The company is also studying a gene therapy study in the Phase 3 trial, SAPPHIRE, to make PH treatment more convenient with just a once quarterly infusion of genetically engineered autologous stem cells from the patient. The company expects enrollment to be completed in 2021, and product launch by 2025. Finally, the company is attempting its hand at the much challenging and lucrative organ manufacturing segment.

The biggest risk weighing down on United Therapeutics valuation is the potential impact of generic erosion of Remodulin. The company depends extensively on its topline on the treprostinil franchise, exposing it to significant business concentration risk.

The company is exposed to R&D failure risk and subsequent contraction in probable growth drivers. The most recent example of such a failed trial is the phase 2/3 DISTINCT study evaluating Unituxin in Injection added to irinotecan compared to irinotecan or topotecan alone in patients with relapsed or refractory SCLC (small cell lung cancer). On February 3, 2020, the company announced that this trial did not meet its primary endpoint of extending OS (overall survival).

According to finviz, the 12-month consensus target price of the company is $122.22. On February 27, Cowen analyst Chris Shibutani upgraded United Therapeutics from Market Perform to Outperform and raised the price target from $119 to $145. On February 25, Wedbush analyst Liana Moussatos raised her price target from $237 to $243 and reiterated Outperform rating for the stock. On February 13, Credit Suisse analyst Martin Auster reiterated the Outperform rating and raised his price target from $113 to $121. On January 31, JPMorgan analyst Jessica Fye revised upwards United Therapeutics rating from Neutral to Overweight and price target from $116 to $120. On December 27, Oppenheimer analyst Hartaj Singh reiterated the Outperform rating and $155 target price.

We see that the overall analyst sentiment and target price have consistently improved for the company since March 2019.

Based on the companys robust product portfolio, strong pipeline, and multiple upcoming catalysts, I believe that $145 is a fair estimate of the true value of the company. I believe that retail investors with above-average risk appetite should consider buying the company on the latest dip in 2020.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Read more here:
United Therapeutics: Buy The Dip - Seeking Alpha

25 new Android games from the week of February 24, 2020 – Android Police

Welcome to our roundup of the new Android games that went live in the Play Store or were spotted by us in the previous week or so. Today I have the official launch of Valve's auto chess title, the Western release of a Dragon Quest gacha game, the soft launch of Electronic Arts' tower defense game Plants vs. Zombies 3, and the arrival of LEGO's free-to-play hero brawler. So without further ado, here are the more notable Android games released during the week of February 24th, 2020.

Looking for the previous roundup editions? Find them here.

Android Police coverage: Valve's Auto Chess competitor Dota Underlords is coming to Android (Update: Season 1 starts today)

Dota Underlords is Valve's take on auto chess, built off of the MOBA Dota 2, and it's been playable on Android since July 2019, though this week marks the official release as well as the beginning of the first season for the title. As expected, the auto-battler offers a $5 subscription pass for anyone that would like to earn extra rewards as they play, and since this week marks the official stable release for mobile, new modes and gameplay elements have arrived to flesh out the title. Sadly, many reviews point to poor balancing, which is something to keep in mind if you haven't played this auto-battler yet.

Monetization: free / no ads / IAPs from $0.99 - $4.99

Android Police coverage: Dragon Quest of the Stars is available for download a day early, but you can't play it yet (Update: Out now)

Dragon Quest of the Stars is a four-year-old mobile RPG from Square Enix that has just made its way to the West. It brings along aging art and game design, and yet includes exorbitant in-app purchases, not to mention a monthly sub that locks ease-of-use features behind a paywall. So not only is this game a cash-in, it's not even new. So while the gacha-based gameplay assuredly offers an addictive grind, expect to pay through the nose if you'd like to advance at a regular pace.

Monetization: free / no ads / IAPs from $0.99 - $79.99

Android Police coverage: Plants vs. Zombies 3 leaves pre-alpha testing, enters soft launch in select territories

This week Plants vs. Zombies 3 left pre-alpha and entered into a soft-launch phase. Right now, the game is officially available in the Philippines and should be coming to new regions as the days move forward, though an in-depth time frame hasn't been provided. So it would seem Electronic Arts is slowly pushing Pv3 out to the public as it continues developing and testing the game to ensure that fans will love it. Of course, if you check out the listed in-app purchase prices below, it's easy to understand why it could be challenging for many fans of the series to get excited about this title.

Monetization: free / contains ads / IAPs from $0.99 - $99.99

Android Police coverage: LEGO Legacy: Heroes Unboxed is a F2P collect-a-thon RPG, now available on the Play Store (Update)

LEGO Legacy: Heroes Unboxed is a free-to-play strategy RPG that stars everyone's favorite LEGO characters, and that's on purpose since this a hero collection game. Yep, if you've ever playedMARVEL Strike Force,Star Wars: Galaxy of Heroes,DC Legends: Battle for Justice,Ninja Turtles: Legends,Disney Heroes: Battle Mode,Looney Tunes World of Mayhem,Might and Magic: Elemental Guardians,Age of Magic, orSummoners War, then you should know exactly what to expect from Heroes Unboxed. More or less, it's a kids game filled with gambling mechanics disguised as mini-figure collecting, which shows LEGO has no qualms emptying the pockets of children for its profits.

Monetization: free / no ads / IAPs from $0.99 - $99.99

ISOLAND 3: Dust of the Universe is the long-awaited sequel to Isoland 2: Ashes of Time, though it looks like the dev opted for a different publisher this time around. More or less, you can expect the same fantastic point-and-click adventure gameplay as the first two titles in the series, all wrapped up in a new story that explores the significance of art.

Monetization: $1.99 / no ads / IAPs from $0.99 - $4.49

Story of a Gladiator is a new release from the creators of Dark Quest and its sequel. Unlike the developer's previous titles, Story of a Gladiator isn't an RPG. It's actually a brawler similar in style to Capcom's beat 'em up games. Of course, this title is themed around fighting in an arena as a gladiator, and it offers 80 enemies, three arenas, 36 battles, and three boss fights. So if you're looking for a quality arcade brawler that won't break the bank, Story of a Gladiator is a solid choice.

Monetization: $2.99 / no ads / no IAPs

Aces of the Luftwaffe - Squadron: Extended Edition offers two separate titles in a single package, which explains the $7.99 price tag. As you would expect, this is a top-down shoot 'em up, and it's themed around the planes that took to the air in WWII. Since the game offers two separate campaigns, you can expect to shoot your way through 50 levels and 12 boss fights. Best of all, the entire game is fully voiced, which adds a level of polish you wouldn't expect from a mobile release. If you love top-down arcade shooters, this one's worth the asking price.

Monetization: $7.99 / no ads / no IAPs

Eri's Forest is an extremely unique tower defense game that offers a 360-degree playing field. Essentially each match will take place on a piece of a tree, and you'll have to revolve the camera around this branch to get a clear picture of the entire field. This makes for exciting matches since you'll have to micromanage your camera as you keep the baddies from reaching your base. This is how you take a tried and true genre and turn it on its head, folksprops to the dev.

Monetization: $7.99 / no ads / no IAPs

SWORDSHOT Demo serves as an early access release for what is essentially a top-down shooter. The thing is, this is a static shooter, and so it will be your job to blast the revolving shields of your enemies in order to take them down. Think of the game as a boss rush mode in your favorite top-down shooter, and that's precisely what you can expect from this release.

Monetization: free / no ads / no IAPs

The Cat in the Hat Invents: PreK STEM Robot Games is an educational game designed to get kids interested in STEM. Of course, most STEM fields require a massive amount of dedication to be successful in them, so it's not like the Cat in the Hat is going to all of a sudden make your kid good at math, but I suppose stoking interests early is still a good thing.

Monetization: free / no ads / no IAPs

This is a bit of an odder listing, but it would appear that Dish Life: The Game is a simulation title all about growing stem cells, of all things. It will be your job to manage the daily activities of a stem cell lab, such as growing and nurturing stem cells. Of course, this is also a game that contains a political bend, so subjects like politics and social issues are present for some reason. Oh, and like most games that were built to focus on a political message instead of fun, this is a title filled with bugs. Imagine that.

Monetization: free / contains ads / no IAPs

Dungeon Quest Action RPG is chiefly a hack-and-slash dungeon crawler that exudes a few roguelike elements. Players will have to level up as they collect new equipment, and there are a few boss fights in the mix, so players should expect a challenge. Best of all, this title isn't some greedy gacha game, so its monetization is straightforward. If you like what you see, you can purchase the entirety of the title through a single in-app purchase.

Monetization: free / contains ads / IAPs $3.49 a piece

Make it perfect is a game for everyone out there that suffers from OCD. I know that I have a peculiar problem where I can't fall asleep if my shoes aren't standing up straight on the floor, and so I can totally get behind a game that's all about unnecessary perfection and tidiness. Essentially it will be your job to clean up each level in the game to the point where things look perfect. Then it's on to the next stage.

Monetization: free / contains ads / IAPs $3.49 a piece

US Conflict is a real-time strategy game that forgoes the general BS you would expect of a mobile RTS title. That means this release offers gameplay that is closer to what you would expect from a PC RTS game, all in the palm of your hands. Really, the only downside I can find with this release is that there are only 12 stages to play through, making for a short experience, but still a fun one.

Monetization: free / contains ads / IAPs $5.99 a piece

It would appear that ZeptoLab has fallen to the wayside much like Rovio, and is now releasing shallow junk, like this endless runner. Maybe if ZeptoLab had jumped into the genre when it was still popular, this release would make more sense, but seeing that this style of game is completely played out, I have to wonder who greenlit this release. I mean, the title works as advertised, but really who cares about yet another pointless endless runner, even if it stars a cute character from a 10-year old mobile game. At the very least, the title's in-app purchases aren't all that bad. It's just a shame ZeptoLab couldn't come up with an original idea.

Monetization: free / contains ads / IAPs from $0.99 - $9.99

Microsoft Sudoku is a release that caught me by surprise. Up until this week, I never heard about the game, but it would appear that's it's been around for a while on competing platforms. Still, it's a surprise to see the title appear on the Play Store without word-one from Microsoft, and it would seem that more than a few people have been able to play the game over the last few months, and so far many of the reviews point to sound bugs and iffy controls.

Monetization: free / contains ads / IAPs from $1.99 - $9.99

Do you love adorable cats? Do you enjoy playing idle games? Well, guess what, Idle Cat Stars is an infectious title that contains both, and it just entered into early access this week. Essentially this is a celebrity cat management game, and so it will be your job to direct the careers of famous felines, such as Angry Cat. So if you'd like to experience what it's like to run the social media campaign for your favorite celebrity feline, then this is the game for you. Of course, like most idle games, the gameplay grows stale quickly, though the monetization in this release isn't as bad as the majority of free-to-play idle games out there.

Monetization: free / contains ads / IAPs from $1.99 - $37.99

With all the PR I received this week about Knockdown Heroes, you'd think this game was actually bringing something new to the table, but of course, it isn't. Essentially this is a title that clones the mechanics of Clash Royale, though there is a little more room for player input since there are a few unique moves in the mix. Sadly the controls aren't all that great, which really hampers player enjoyment.

Monetization: free / contains ads / IAPs from $0.99 - $49.99

RPG Liege Dragon is the latest release from Kemco to offer an English translation. As expected, this is a generic turn-based RPG that not only costs $9 but also contains in-app purchases that range all the way up to $49.99 per item. Why a $9 mobile game contains IAPS that high, I do not know, and I wouldn't recommend spending $9 to find out either. No wonder nobody talks about Kemco anymore.

Monetization: $8.99 / contains ads / IAPs from $0.99 - $49.99

Saint Seiya Shining Soldiers is the latest release from Bandai Namco, and as you can see, it's themed around the Japanese manga series Saint Seiya: Knights of the Zodiac. Like most Bandai mobile games, this is a battle-based RPG, though the UI is rough, and you'll have to constantly download new sections of the game, even if you opt for the bulk-download option, which is really annoying.

Monetization: free / no ads / IAPs from $0.99 - $79.99

Dragon Raja is a drop-dead gorgeous mobile MMO that was built using Unreal Engine 4. Much like Black Desert Mobile, this game offers a fantastic character creator, but sadly all the other annoyances found in similar MMOs make an appearance. This means auto-questing and auto-combat are present, and there doesn't appear to be an on-screen map, so auto-questing is definitely a requisite. Still, this is one of the best looking MMOs on Android to date, and it's worth exploring if you don't mind the annoyances of the genre, like heavy monetization and endless grinding.

Monetization: free / no ads / IAPs from $0.99 - $99.99

Okay, I'm just about sick of seeing all of the idle games that are constantly released on the Google Play Store. The majority are low-effort garbage that offers the exact same gameplay mechanics as the next. And then in comes Dream Blue Ocean, an idle game that actually tries to do things differently. Sure, you'll still find yourself furiously tapping on the screen during certain sections of the title, but more or less, this is a relaxing game all about fishing and exploring the ocean, and let me tell you, it looks great too. Sadly the game is still filled with ridiculous monetization, but at least its devs bothered to put some thought into its gameplay.

Monetization: free / contains ads / IAPs from $0.99 - $99.99

Bio Inc. Nemesis - Plague Doctors used to be called Bio Inc 2: Rebel Doctor Plague, and you can even see in one of the screenshots that this is indeed Bio Inc. 2. Now I don't know why the devs chose to change the name, but it would appear that the title is now officially available, despite the fact we covered the previous release at the tail end of last year. More or less, this is a virus simulation game, much like the previous title in the series, though it would appear killing humans (instead of a virus) is more of a goal this time around. So far, user reviews have not been kind, pointing to greedy monetization and buggy gameplay.

Monetization: free / contains ads / IAPs from $0.99 - $99.99

Knighthood comes from King, the developer behind the Candy Crush series, and so this release is a big departure for the company since the game is a turn-based RPG. Considering that this is a King release, you can expect extremely heavy monetization as well as a boatload of false roadblocks designed to slow down your journey. Sure, the game looks great, but that's really all it has going for it.

Monetization: free / no ads / IAPs from $1.99 - $99.99

Galaxy Airforce War is a free-to-play SHMUP that plays just like the rest. Gridining is very much a thing, and so is constant death, and for some reason, the game plays in landscape mode instead of portrait. This design choice makes it difficult to see what's going on, and for a shooter, it's detrimental to the gameplay. You know what else is detrimental, filling a SHMUP with a boatload of in-app purchases. Last I looked, there isn't a single top-down shooter on this planet worth spending $100 on.

Monetization: free / contains ads / IAPs from $2.99 - $99.99

If you have an application in mind for the next issue of the roundup, feel free to send us an email and let us know.

See more here:
25 new Android games from the week of February 24, 2020 - Android Police

Parents of son’s who suffered from cancer to take on Isle of Wight challenge – Bournemouth Echo

THE PARENTS of a boy from Poole who lost his battle with cancer three years ago are urging the public to join them on a charity walk in his memory.

Soon after celebrating his 18th birthday, Lucas Dennett was diagnosed with acute lymphoblastic leukaemia in December 2017.

Despite the best efforts of the doctors and nurses on the Durlston Ward at Poole Hospital, Lucas passed away nine months later.

In August 2017, his older brother Alex, 22, was diagnosed with Hodgkins Lymphoma. He underwent a gruelling course of chemotherapy, only for the cancer to return in December 2018, with Alex requiring a stem cell transplant.

Alex is now recovering.

Lucas and Alexs mother and stepfather, Clare and Simon Blissett, are now focused on raising as much money as possible for Leukaemia Educating and Fundraising, or LEAF, the charity that have supported them closely.

Simon, 44, said: I cant put into words what LEAF has done for our family. The charity has helped to rebuild our shattered lives.

Life will always be different for us now but thanks to LEAF we can smile, laugh and remember the good times, which is something we never thought wed be able to do.

The couple are midway through their training for the Isle of Wight Challenge in May, where theyll walk 106km non-stop around the entire coastline of the island to raise money for Dorset-based charity LEAF.

Clare and I want to do all we can to raise as much money as possible for LEAF, Simon added.

The work they do makes a huge difference to those people going through the hell of leukaemia and other forms of blood cancers.

Thats why I want as many people as possible to join us and take on the Isle of Wight Challenge in support of LEAF.

Participants can take on the full challenge of 106km in one go or complete it over two days.

Alternatively, they can take part in the half challenge of around 50km, or even the 25km quarter challenge.

LEAF supports blood cancer patients across Dorset and Hampshire.

The charitys founder, Natasha Hunt, herself a leukaemia survivor, worked closely with the the family during Lucass nine month battle with Leukaemia and Alexs battle with Hodgkins Lymphoma.

Having completed the full challenge last year in aid of The Teenage Cancer Trust, Simon wants to repeat his efforts and raise even more money for Leukaemia Educating and Fundraising.

Talking about his experience last year, Simon said: It was a great experience incredibly challenging, but so rewarding. Crossing the finishing line was such an emotional moment, knowing Id done it for Lucas.

I promised him Id raise 1million for charity, and I would love as many people as possible to join me on this walk, all raising money together in memory of our amazing son Lucas.

To sign up to the challenge and join Simons team to raise funds for LEAF, visit http://www.isleofwightchallenge.com.

If you cant join Simon and Clare for the Isle of Wight Challenge, but you still want to support them, you can sponsor them at: https://www.justgiving.com/fundraising/simon-blissett7.

Read the original post:
Parents of son's who suffered from cancer to take on Isle of Wight challenge - Bournemouth Echo

SpaceX Targeting March 6 for Launch of its 20th Resupply Mission to International Space Station | – SpaceCoastDaily.com

coverage of launch from Cape Canaveral Air Force Station will air on Space Coast Daily TVSpaceXs Dragon lifting off on a Falcon 9 rocket from Space Launch Complex 40 at Cape Canaveral Air Force Station in Florida with research, equipment, cargo and supplies that will support dozens of investigations aboard the International Space Station. (SpaceX image)

BREVARD COUNTY CAPE CANAVERAL AIR FORCE STATION, FLORIDA NASA commercial cargo provider SpaceX is targeting 11:50 p.m. Friday, March 6, for the launch of its 20th resupply mission to the International Space Station.

Live coverage of the launch from Cape Canaveral Air Force Station in Florida will air on Space Coast Daily TV with prelaunch events Thursday, March 5 and March 6.

The NASA-contracted Dragon spacecraft will be filled with supplies and payloads, including critical materials to directly support dozens of the more than 250science and research investigationsthat will take place during Expeditions 62 and 63.

In addition to bringing research to station, the Dragons unpressurized trunk will transport ESAs (European Space Agency) Bartolomeo, a new commercial research platform set to be installed on the exterior of the orbiting laboratory.

Dragon will reach its preliminary orbit about 10 minutes after launch. It will then deploy its solar arrays and begin a carefully choreographed series of thruster firings to reach the space station.

When it arrives March 9, Expedition 62 Flight Engineer Jessica Meirof NASA will grapple Dragon, with Andrew Morganof NASA acting as a backup.

The station crew will monitor Dragon functions during rendezvous. After Dragons capture, mission control at NASAs Johnson Space Center in Houston will send ground commands for the stations arm to rotate and install it on the bottom of the stations Harmony module.

Full mission coverage is as follows (all times Eastern):

Thursday, March 5

3 p.m. NASA Social, Whats on Board science briefing from NASAs Kennedy Space Center in Florida. This briefing will highlight the following research:

Jennifer Buchli, deputy chief scientist for NASAs International Space Station Program Science Office, will share an overview of the research being conducted aboard the space station and how it benefits exploration and humanity.

Michael Roberts, interim chief scientist for the International Space Station U.S. National Laboratory, will discuss the labs work in advancing science in space, and in developing partnerships that drive industrialization through microgravity research.

Bill Corely, director of business development for Airbus Defence and Space, and Bartolomeo Project Manager Andreas Schtte, will discuss the new external science platform,Bartolomeo.

Chunhui Xu, associate professor at Emory University School of Medicine, and principal investigator for the Generation of Cardiomyocytes from Induced Pluripotent Stem Cells (MVP Cell-03) experiment, will discuss the study on the generation of specialized heart muscle cells for use in research and clinical applications. Chief Scientist of Techshot, Gene Boland, will share how the Multi-use Variable-g Platform will facilitate this experiment.

Paul Patton, senior manager, front end innovation and regulatory, for Delta Faucet, and Garry Marty, principal product engineer for Delta Faucet, will discuss theDroplet Formation Study, which evaluates water droplet formation and water flow of Delta Faucets H2Okinetic showerhead technology. This research in microgravity could help improve the technology, creating better performance and improved user experience while conserving water and energy.

Aaron Beeler, professor of medicinal chemistry at Boston University and principal investigator, and Matthew Mailloux, co-investigator, will discussFlow Chemistry Platform for Synthetic Reactions on ISS, which will study the effects of microgravity on chemical reactions, as a first step toward on-demand chemical synthesis on the space station.

Friday, March 6

4 p.m. Prelaunch news conference from Kennedy with representatives from NASAs International Space Station Program, SpaceX, and the U.S. Air Forces 45th Space Wing. Participants include:

Joel Montalbano, deputy manager for International Space Station Program

Jennifer Buchli, deputy chief scientist for International Space Station Program

Hans Koenigsmann, vice president, Build and Flight Reliability at SpaceX

Mike McAleenan, launch weather officer, U.S. Air Force 45th Space Wing

11:30 p.m. NASA TV launch coverage begins for the 11:50 p.m., launch.

Monday, March 9

4:30 a.m. NASA TV coverage begins of Dragon arrival to the station and capture. Capture is scheduled for approximately 6 a.m.

7:30 a.m. NASA TV coverage begins of Dragon installation to the nadir port of the Harmony module of the station

Dragon will remain at the space station for about four weeks, after which the spacecraft will return to Earth with research and cargo.

CLICK HERE FOR BREVARD COUNTY NEWS

Click here to contribute your news or announcements Free

Go here to see the original:
SpaceX Targeting March 6 for Launch of its 20th Resupply Mission to International Space Station | - SpaceCoastDaily.com